CLXClorox Co. /de/
This year, Clorox has to prove it can sustain its recent momentum and deliver on its FY27 guidance, with the October 28 earnings release serving as the next catalyst. The stock is currently anchored at $87.80, with a modeled bull target of $96.88 and a bear fallback of $84.77, leaning slightly toward the bull path. The earnings print is a critical test, as the historical bull probability for earnings releases in the sector is 45%, but the current macro environment suggests moderate volatility. Recent guidance leaned bearish, yet the last print was bullish, creating a mixed signal that the market is still digesting.
The Read
Clorox's stock rallied on Q2 FY26 earnings due to management's confidence in margin expansion and product innovation, fell sharply amid margin pressure and CRM issues, rebounded slightly on Q3 results, declined further on weak Q4 guidance, then surged again on Q2 2026 earnings and upbeat FY27 guidance.
The schedule
No upcoming catalysts on the current packet.
Past
- Fri7Aug
Actual outcome: Bull · $106.95 at outcome
Clorox reported earnings in line with expectations, with EPS actual of $1.34 versus the estimate of $1.34. The company provided upbeat full-year FY27 guidance, signaling stabilization in demand and confidence in its strategic initiatives. These positive forward-looking statements, combined with the completion of ERP implementation and plans to offset supply-chain inflation, drove the stock higher despite the neutral earnings report.
- Tue4Aug
Actual outcome: Bull · $106.51 at outcome
Clorox (CLX) reported an EPS actual of 4.98, matching the estimate, and provided initial FY27 guidance. Despite margin pressures and a trailing net margin of 8.7%, the stock rallied due to positive sentiment around its long-term strategic direction, including rebranding efforts and partnerships, which signaled stability and growth potential, driving the price above the bull target.
- Thu28May
Actual outcome: Bear · $81.01 at outcome
CLX reported earnings below expectations and provided weaker-than-anticipated guidance, leading to a sharp decline. The stock reacted to lower-than-expected revenue and EPS, along with concerns about near-term growth prospects. The move reflects investor disappointment in the company's performance relative to market expectations. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-30: -15.3% from 2026-08-27 (~2.3σ). Target date 2026-06-02 reached; move through 2026-09-30 observed.
CLX reported earnings below expectations and provided weaker-than-anticipated guidance, leading to a sharp decline. The stock reacted to lower-than-expected revenue and EPS, along with concerns about near-term growth prospects. The move reflects investor disappointment in the company's performance relative to market expectations. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-30: -15.3% from 2026-08-27 (~2.3σ). Target date 2026-06-02 reached; move through 2026-09-30 observed.
- Tue5May
Actual outcome: Mixed · $88.06 at outcome
CLX reported an EPS actual of 4.98, matching the estimate, and the stock rose 3.4% from the event date to the outcome date. The positive sentiment around consumer defensive stocks and the company's consistent dividend history likely reinforced investor confidence, driving the rally despite the lack of an earnings beat.
- Mon30Mar
Actual outcome: Bear · $95.36 at outcome
Clorox shares fell well below the bear floor of $110.50 as the company struggled with lower profits, slowing sales volumes, and the lingering effects of a painful CRM system transition. Analysts largely issued 'Reduce' ratings, reflecting ongoing concerns over margin pressures and operational setbacks that overshadowed the company's dividend yield and digital optimization efforts.
- Tue3Feb
Actual outcome: Bull · $116.52 at outcome
Clorox reported mixed Q2 results, missing EPS estimates ($1.39 vs $1.43) due to volume declines and cost pressures, though sales reportedly beat expectations. The stock rallied significantly past the bull target because management confirmed its full-year EPS guidance and emphasized upcoming margin expansion and product innovation, signaling confidence that cost-saving measures would overcome near-term headwinds. This forward-looking stability and perceived cheap valuation drove the sustained positive price action.
